Skip to main content
OpenTrials
Completed

NCT Number: NCT01915407

AggreGuide 325 mg. Aspirin Study for Aspirin Induced Platelet Dysfunction

To test the AggreGuide A-100 AA Assay's effectiveness for detecting aspirin induced platelet dysfunction.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Platelet Dysfunction Due to Aspirin Ingestion

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Aggredyne, Inc.

Houston, Texas, 77099, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • over 18

Exclusion criteria

  • on aspirin in prior week
  • medical history of platelet disorders
  • contraindications to aspirin

Treatment and study plan

Primary outcomes

  1. Platelet Activity Index (PAI) before and after ingestion of aspirin

    Time frame: 2 - 30 hours post aspirin ingestion

    PAI is the proprietary reporting unit of the Aggreguide. It is related to the amount of platelet aggregation in the sample of whole blood.

Sponsors and collaborators

Lead sponsor

Aggredyne, Inc.

Industry

Registry information

Important dates

Study start
2013
Primary completion
2013
Study completion
2013
First posted
Aug 2, 2013
Registry last updated
Aug 2, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.